8967 related articles for article (PubMed ID: 20689758)
21. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations.
Niehr F; von Euw E; Attar N; Guo D; Matsunaga D; Sazegar H; Ng C; Glaspy JA; Recio JA; Lo RS; Mischel PS; Comin-Anduix B; Ribas A
J Transl Med; 2011 May; 9():76. PubMed ID: 21609436
[TBL] [Abstract][Full Text] [Related]
22. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations.
Comin-Anduix B; Chodon T; Sazegar H; Matsunaga D; Mock S; Jalil J; Escuin-Ordinas H; Chmielowski B; Koya RC; Ribas A
Clin Cancer Res; 2010 Dec; 16(24):6040-8. PubMed ID: 21169256
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.
Basile KJ; Le K; Hartsough EJ; Aplin AE
Pigment Cell Melanoma Res; 2014 May; 27(3):479-84. PubMed ID: 24422853
[TBL] [Abstract][Full Text] [Related]
24. BRAF as a target for cancer therapy.
Dienstmann R; Tabernero J
Anticancer Agents Med Chem; 2011 Mar; 11(3):285-95. PubMed ID: 21426297
[TBL] [Abstract][Full Text] [Related]
25. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A
PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
27. Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment.
Ng YK; Lee JY; Supko KM; Khan A; Torres SM; Berwick M; Ho J; Kirkwood JM; Siegfried JM; Stabile LP
Melanoma Res; 2014 Jun; 24(3):207-18. PubMed ID: 24709886
[TBL] [Abstract][Full Text] [Related]
28. BRAF
Lunavat TR; Cheng L; Einarsdottir BO; Olofsson Bagge R; Veppil Muralidharan S; Sharples RA; Lässer C; Gho YS; Hill AF; Nilsson JA; Lötvall J
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5930-E5939. PubMed ID: 28684402
[TBL] [Abstract][Full Text] [Related]
29. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Müller J; Krijgsman O; Tsoi J; Robert L; Hugo W; Song C; Kong X; Possik PA; Cornelissen-Steijger PD; Geukes Foppen MH; Kemper K; Goding CR; McDermott U; Blank C; Haanen J; Graeber TG; Ribas A; Lo RS; Peeper DS
Nat Commun; 2014 Dec; 5():5712. PubMed ID: 25502142
[TBL] [Abstract][Full Text] [Related]
30. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.
Yadav V; Zhang X; Liu J; Estrem S; Li S; Gong XQ; Buchanan S; Henry JR; Starling JJ; Peng SB
J Biol Chem; 2012 Aug; 287(33):28087-98. PubMed ID: 22730329
[TBL] [Abstract][Full Text] [Related]
31. Molecular alterations associated with acquired resistance to BRAFV600E targeted therapy in melanoma cells.
Szász I; Koroknai V; Kiss T; Vízkeleti L; Ádány R; Balázs M
Melanoma Res; 2019 Aug; 29(4):390-400. PubMed ID: 30741840
[TBL] [Abstract][Full Text] [Related]
32. The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204).
Xing J; Liu R; Xing M; Trink B
Biochem Biophys Res Commun; 2011 Jan; 404(4):958-62. PubMed ID: 21185263
[TBL] [Abstract][Full Text] [Related]
33. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.
Yang H; Higgins B; Kolinsky K; Packman K; Go Z; Iyer R; Kolis S; Zhao S; Lee R; Grippo JF; Schostack K; Simcox ME; Heimbrook D; Bollag G; Su F
Cancer Res; 2010 Jul; 70(13):5518-27. PubMed ID: 20551065
[TBL] [Abstract][Full Text] [Related]
34. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
Bollag G; Hirth P; Tsai J; Zhang J; Ibrahim PN; Cho H; Spevak W; Zhang C; Zhang Y; Habets G; Burton EA; Wong B; Tsang G; West BL; Powell B; Shellooe R; Marimuthu A; Nguyen H; Zhang KY; Artis DR; Schlessinger J; Su F; Higgins B; Iyer R; D'Andrea K; Koehler A; Stumm M; Lin PS; Lee RJ; Grippo J; Puzanov I; Kim KB; Ribas A; McArthur GA; Sosman JA; Chapman PB; Flaherty KT; Xu X; Nathanson KL; Nolop K
Nature; 2010 Sep; 467(7315):596-9. PubMed ID: 20823850
[TBL] [Abstract][Full Text] [Related]
35. Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.
Narita Y; Okamoto K; Kawada MI; Takase K; Minoshima Y; Kodama K; Iwata M; Miyamoto N; Sawada K
Mol Cancer Ther; 2014 Apr; 13(4):823-32. PubMed ID: 24448821
[TBL] [Abstract][Full Text] [Related]
36. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
37. Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma.
Fedorenko IV; Fang B; Munko AC; Gibney GT; Koomen JM; Smalley KS
Proteomics; 2015 Jan; 15(2-3):327-39. PubMed ID: 25339196
[TBL] [Abstract][Full Text] [Related]
38. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.
Girotti MR; Pedersen M; Sanchez-Laorden B; Viros A; Turajlic S; Niculescu-Duvaz D; Zambon A; Sinclair J; Hayes A; Gore M; Lorigan P; Springer C; Larkin J; Jorgensen C; Marais R
Cancer Discov; 2013 Feb; 3(2):158-67. PubMed ID: 23242808
[TBL] [Abstract][Full Text] [Related]
39. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance.
Wroblewski D; Mijatov B; Mohana-Kumaran N; Lai F; Gallagher SJ; Haass NK; Zhang XD; Hersey P
Carcinogenesis; 2013 Feb; 34(2):237-47. PubMed ID: 23087082
[TBL] [Abstract][Full Text] [Related]
40. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
